Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Opdivo plus Yervoy led to higher response rates and longer survival than Opdivo alone.
A new study shows that people with the liver disease have substantial financial burden that can impact their care.
Researchers analyzed cancer outcomes among a large group of South Koreans with hepatitis B virus.
Immunotherapy did not improve overall survival but led to fewer side effects and better quality of life.
Phase III study misses statistical threshold, but the immunotherapy appears to show some benefit.
Study in China sees an association with several cancer types, especially gastrointestinal malignancies.
Learning to live well with liver disease, even at it’s worst stages, is possible if you know how to.
Keytruda showed modest benefits for people with hepatocellular carcinoma, and combining Opdivo with Yervoy improved outcomes.
Between August 2018 and January 2019, the FDA doubled the number of liver cancer treatments.
With the approval of Cyramza, there are now five targeted therapies for hepatocellular carcinoma.
Do you know your liver cancer risk?
People who took Viread were about two thirds less likely to develop HCC, but this could be related to other factors as well.
Keytruda and Opdivo showed antitumor activity in some patients and acceptable side effects in real-world use.
Karen’s tribute to Gavin on his 21st birthday. This sweet boy died, donated his organs, and Karen carries his liver.
Hepatitis C can lead to a variety of complications such as cirrhosis, portal hypertension, liver cancer, and liver transplant.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.